View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
September 5, 2018updated 12 Jul 2022 1:12pm

Synlogic reports positive interim results from SYNB1618 trial

Synlogic has reported positive interim data from the healthy volunteer (HV) arm of its ongoing Phase l/lla study of SYNB1618 to treat phenylketonuria (PKU) after meeting the trial’s primary objective.

Synlogic has reported positive interim data from the healthy volunteer (HV) arm of its ongoing Phase l/lla study of SYNB1618 to treat phenylketonuria (PKU) after meeting the trial’s primary objective.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

In the first portion of the trial, Synlogic examined SYNB1618 in comparison with placebo (PBO) in single-ascending dose (SAD) and multiple-ascending dose (MAD) cohorts of HVs.

This portion was designed to demonstrate safety and tolerability of SYNB1618 in HVs and to find a suitable dose of the drug for evaluation in patients with PKU.

Results from this portion of the trial are similar to preclinical studies and have shown that oral administration of SYNB1618 led to significant dose-dependent production of biomarkers specifically related to SYNB1618 activity to demonstrate proof-of-mechanism.

Synlogic interim president and CEO and chief medical officer Aoife Brennan said: “The significant dose-dependent production of SYNB1618-specific biomarkers in healthy volunteers is an exciting first step towards delivering a potential therapy for patients with PKU.

“The significant dose-dependent production of SYNB1618-specific biomarkers in healthy volunteers is an exciting first step towards delivering a potential therapy for patients with PKU.”

“We have identified a dose for the next phase of our ongoing trial in patients with PKU and we look forward to expanding on these interim results when we report top-line data from the patient treatment arm of this trial in mid-2019.

“Importantly, the data also demonstrates the potential for our Synthetic Biotic platform to address conditions in which an engineered living medicine can be designed to perform a specific metabolic function within the gastrointestinal tract.”

The Phase l/lla trial is a randomised, double-blind, PBO-controlled study of orally administered SYNB1618.

It aims to analyse the ascending doses of SYNB1618 administered on a single day, along witth multiple-ascending doses given over a period of seven days.

The trial’s primary objective was to evaluate the safety and tolerability of SYNB1618 in HVs and to indentify an appropriate dose to evaluate in patients with PKU.

Its secondary objectives include characterisation of microbial kinetics of SYNB1618 in feces, as measured by qPCR, and gastrointestinal (GI) tolerability, assessed by GI-related adverse events.

Exploratory goals of the trial were evaluation of pharmacodynamic effects of SYNB1618, including previously identified biomarkers of SYNB1618 activity, tricyclic antidepressant (TCA) level in plasma and HA in urine.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena